Targets › CSNK2A1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2030.
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. (UniProt, P68400)
Open in Phaseline: the race on CSNK2A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Milton S. Hershey Medical Center | Silmitasertib (CX-4945) Casein kinase II alpha inhibitor | CSNK2A1 | Phase 1 | Neuroblastoma | Nov 2030 |
Neuroblastoma (1)
small molecule (1)
Milton S. Hershey Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.